samedan logo
 
 
spacer
home > advertise
ADVERTISING OPPORTUNITIES
Why Advertise with Samedan?

 

Samedan's range of specialist titles spans the full spectrum of pharmaceutical development, from innovation to patient, and is designed to meet the broad
needs of an industry built on high-quality information, communication, and expertise.

With a history going back more than a decade, Samedan's clients range from long-established industry leaders to the most recent start-ups and university spin-outs.
Many clients have advertised across our entire range for years and have come to
appreciate a strong and cooperative relationship with us.

Samedan is committed to providing the perfect editorial platform for your advert.
That is why our featured articles take an opinion-led, non-promotional view of the industry. This ensures that every advert enjoys maximum impact with each title's readership of 10,000+ key decision makers.

For further information about each of our titles, follow the links below. Each of our advertising executives can be contacted at the email addresses below and will be
pleased to discuss how Samedan can meet your needs.

Tel: +44 (0)20 7724 3456
Fax: +44 (0)20 7403 7747

European Pharmaceutical Contractor
Louise White: louise@samedanltd.com

European BioPharmaceutical Review
David Hirsh: david@samedanltd.com

International Clinical Trials
Louise White: louise@samedanltd.com

Pharmaceutical Manufacturing and Packing Sourcer
Nicholas Matthews: nick@samedanltd.com

Innovations in Pharmaceutical Technology
David Hirsh: david@samedanltd.com



spacer

Industry Events

The Universe of Pre-filled Syringes and Injection Devices

22-23 October 2019, The Swedish Exhibition & Congress Centre Gothia Towers Hotel

PDA’s Universe of Pre-filled Syringes and Injection Devices has become the must-attend meeting for everyone working in the field, and is now the world’s largest conference on this subject
More info >>

News and Press Releases

Clinical and Regulatory Operational Excellence Forum

1. Innovative technologies are expected to take clinical development, licensing, and other regulatory processes to the next level in the future. What do you see are the biggest challenges facing companies when trying to cope with continued data growth in a fast changing environment? Pharmaceutical companies are heavily regulated and introducing change needs proof of acceptance by the authorities. The chance that authorities do not agree with that change makes the industry risk averse. Changes in a stable GxP environment are almost by default seen as a risk, however, not adapting to new technologies should also be seen as a risk! Therefore, ICH developed the ICH Q8, Q9, Q10, Q11, and Q12 guidelines, to anticipate change and implement changes much faster, with less of a regulatory burden. Nevertheless, industry is not picking up with the desired pace. Why not?
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement